RECENT NEWS

Research scientists have identified five specific blood proteins that can accurately predict a person’s risk for developing a serious form of liver disease as early as 16 years before they experience symptoms, enabling early intervention and possible prevention and treatment, according to a study to be presented at Digestive Disease Week.

A groundbreaking UK research network has been launched to uncover how gut health influences the brain, immune system and mental wellbeing. The project will run for four years and has received £4.5 million in funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

PredxBio, a pioneer in AI-powered spatial biomarker discovery, is to partner with Hamamatsu to deliver next-generation spatial biology solutions for cancer research and therapeutic development.

Complete Genomics, a leading innovator in genomic sequencing, has announced a collaboration with Velsera, a leading global healthcare technology company, to deliver an end-to-end genetic testing solution that integrates DNBSEQ sequencing technology with Velsera's Clinical Genomics Workspace (CGW) data analysis solution.

Gestalt, a leading innovator in AI-powered digital pathology solutions, has raised $7.5 million Series A financing to further develop its AI-powered pathology platform, PathFlow.

Medtech firm Sophia Genetics is to expand its ongoing collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS liquid biopsy application.

Roche has announced today that the US Food and Drug Administration (FDA) granted Breakthrough Device Designation for the VENTANA TROP2 (EPR20043) RxDx Device. This is the first Breakthrough Device Designation to be granted for a computational pathology companion diagnostic (CDx) device.

AnalytiChem, manufacturer of laboratory equipment, reagents and consumables, has introduced Redipo, a new range of ready-to-use culture media.

Paige, together with NHS Wales, has announced the launch of a new pilot project at Betsi Cadwaladr University Health Board (BCUHB). The project will evaluate how Paige’s AI-assisted diagnostic application, Paige PanCancer Detect, can streamline pathology workflows and enhance patient care by triaging routine clinical cases.

The UK Health Security Agency (UKHSA), has just published an overarching public health strategy for controlling and eliminating mpox (previously referred to as monkeypox) across the UK, focusing on the next 12-month period.

In collaboration with the National Institute for Health and Care Research (NIHR), the UK government has awarded £2.4 million to progress the development of a novel AI-driven blood test, known as miONCO-Dx.

Beckman Coulter Life Sciences has launched the OptiMATE Gradient Maker, a groundbreaking instrument designed to automate the process of density gradient ultracentrifugation (DGUC).

A new study provides solutions to the pressing need to identify factors that influence Alzheimer’s disease (AD) risk or resistance while providing an avenue to explore potential biological markers and therapeutic targets.

A landmark study presented at ESCMID Global 2025 has revealed that over 3 million children worldwide lost their lives in 2022 due to antimicrobial resistance (AMR)-related infections.

UK Research and Innovation’s Biotechnology and Biological Sciences Research Council (BBSRC) has announced £9 million in funding for a variety of bioscience projects, with its prestigious 2024 Fellowships scheme supporting 19 future science leaders

Roche has announced an investment of US $50 billion into the United States of America in the next five years across its pharmaceutical and diagnostics divisions.

ARUP Laboratories now provides a blood test for phosphorylated tau 217 (pTau 217) to assist in identifying whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer's disease (AD) pathology.

Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, has announced a strategic partnership with the Accelerated Cure Project (ACP), a nonprofit organisation dedicated to accelerating research and improving outcomes for people with multiple sclerosis (MS).

Leidos is committing $10 million to accelerate the use of artificial intelligence for detecting and managing diseases, in collaboration with the University of Pittsburgh's Computational Pathology and AI Center of Excellence (CPACE).

A pioneering study presented at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient groups, including neonates, children and pregnant women. This study is the first to evaluate IL-6’s diagnostic performance in a real-world cohort across all three populations.